RT Journal Article
SR Electronic
T1 The comparability of Anti-Spike SARS-CoV-2 antibody tests is time-dependent: a prospective observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.26.21262426
DO 10.1101/2021.08.26.21262426
A1 Perkmann, Thomas
A1 Mucher, Patrick
A1 Perkmann-Nagele, Nicole
A1 Radakovics, Astrid
A1 Repl, Manuela
A1 Koller, Thomas
A1 Schmetterer, Klaus G
A1 Bigenzahn, Johannes W
A1 Leitner, Florentina
A1 Jordakieva, Galateja
A1 Wagner, Oswald F
A1 Binder, Christoph J
A1 Haslacher, Helmuth
YR 2021
UL http://medrxiv.org/content/early/2021/09/05/2021.08.26.21262426.abstract
AB Objectives Various commercial anti-Spike SARS-CoV-2 antibody tests are used for studies and in clinical settings after vaccination. An international standard for SARS-CoV-2 antibodies has been established to achieve comparability of such tests, allowing conversions to BAU/ml. This study aimed to investigate the comparability of antibody tests regarding the timing of blood collection after vaccination.Methods For this prospective observational study, antibody levels of 50 participants with homologous AZD1222 vaccination were evaluated at 3 and 11 weeks after the first dose and 3 weeks after the second dose using two commercial anti-Spike binding antibody assays (Roche and Abbott) and a surrogate neutralization assay.Results The correlation between Roche and Abbott changed significantly depending on the time point studied. Although 3 weeks after the first dose, Abbott provided values three times higher than Roche, 11 weeks after the first dose, the values for Roche were twice as high as for Abbott, and 3 weeks after the second dose even 5-6 times higher.Conclusions The comparability of quantitative anti-Spike SARS-CoV-2 antibody tests is highly dependent on the timing of blood collection after vaccination. Therefore, standardization of the timing of blood collection might be necessary for the comparability of different quantitative SARS-COV-2 antibody assays.Competing Interest StatementThe Department of Laboratory Medicine received compensation for advertisement on scientific symposia from Roche and Abbott and holds a grant for evaluating an in vitro diagnostic device from Roche.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Medical University of Vienna ethics committee (1066/2021) and conforms with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available for interested researchers in compliance with the GDPR upon request from the corresponding author.